| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:glaxosmithkline [2022/02/12 00:52] pamela | pharmaceutical_companies:glaxosmithkline [2022/10/06 18:25] (current) pamela [[[:Google]] Partnership] |
|---|
| **GlaxoSmithKline**, often shortened to **GSK**, is a multinational [[:pharmaceutical_companies|pharmaceutical company]] headquartered in London, England with offices in the United States and Singapore.((//Headquarters.// GlaxoSmithKline. Retrieved February 8, 2022, from https://archive.ph/avDju)) ((//GlaxoSmithKline.// Drugs. Retrieved February 8, 2022, from https://www.drugs.com/manufacturer/glaxosmithkline-62.html)) | **GlaxoSmithKline**, often shortened to **GSK**, is a multinational [[:pharmaceutical_companies|pharmaceutical company]] headquartered in London, England with offices in the United States and Singapore.((//Headquarters.// GlaxoSmithKline. Retrieved February 8, 2022, from https://archive.ph/avDju)) ((//GlaxoSmithKline.// Drugs. Retrieved February 8, 2022, from https://www.drugs.com/manufacturer/glaxosmithkline-62.html)) |
| |
| ===== COVID-19 ===== | ===== Operations ===== |
| | |
| | ==== Acquisitions ==== |
| | |
| | In 2005, GSK acquired the [[:canada:British Columbia]]-based [[ID Biomedical]] for $1.7 billion.((//GlaxoSmithKline buys Vancouver’s ID Biomedical for $1.7 billion.// (2005, September 7). CBC News. https://archive.ph/q29Uu)) ID Biomedical was a biotechnology company dedicated to the manufacturing and development of innovative [[:vaccines|vaccine products]], including [[:influenza vaccines]].((//FOI Request - HTH-2015-51828.// (2016, February 12). Government of British Columbia. https://web.archive.org/web/20220428045844/http://docs.openinfo.gov.bc.ca/Response_Package_HTH-2015-51828.pdf)) |
| | |
| | ==== Research Funding ==== |
| | |
| | On November 10, 2011, GSK announced the launch of the $50 million GSK Canada Life Sciences Innovation Fund to advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research.((Robinson, A., & Minicucci, D. (2011, November 10). //GlaxoSmithKline Inc. Launches $50 Million Life Sciences Innovation Fund in Canada.// Wayback Machine; GlaxoSmithKline. https://web.archive.org/web/20160505194118/http://ca.gsk.com/media/525823/2011-11-10.pdf)) |
| | |
| | ==== Google Partnership ==== |
| | {{ :pharmaceutical_companies:gsk_google_verily.png?400|}} |
| | Google Parent and GlaxoSmithKline Are Creating a $715 Million Bioelectronics Firm. |
| | |
| | GSK and [[:Google]] Alphabet's Verily create $715M joint venture in bioelectronics |
| | by Ben Adams | Augist 1, 2016 |
| | |
| | GlaxoSmithKline ($GSK) has announced a major new joint venture with [[:Verily]] --once [[:Google Life Sciences]] --as the two join forces with the hope of creating the first generation of bioelectronic medicines for chronic diseases. |
| | |
| | GSK has been working on this bioelectronic approach since 2012--an approach that aims to disrupt certain electronic signals in the body through tiny implanted devices in the hope of altering the pathways of a number of diseases and conditions. |
| | |
| | It’s stumped up around $50 million in VC cash in that time, but today is taking a much larger leap into this burgeoning area where tech meets biology by putting down £540 million ($715 million) over the next 7 years into a JV with Verily, which will focus on building devices that target arthritis, diabetes and asthma. |
| | |
| | Verily, a part of [[:Alphabet]] ($GOOG) and graduating from its secretive [[:Google X division]], has recently become its own unit, with a focus on big data and devices, such as a "smart" contact lens and surgical robots. |
| | |
| | The company has already attracted the attention of a number of Big Pharmas, having tie-ups with [[:Sanofi]] ($SNY) in diabetes and already signing a JV with [[:Johnson & Johnson]] ($JNJ) to create a company known as Verb Surgical, which aims to make new kinds of robotic surgical systems. It also has a deal with [[:Dexcom]] ($DXCM) that has seen the two publicly declare their ambition to launch a mini glucose monitor by 2018. |
| | |
| | Its latest iteration, called [[:Galvani Bioelectronics]] (after the Italian 18th century pioneer in the field of bioelectricity Luigi Aloisio Galvani), will be 55% owned by GSK and 45% by Verily. The R&D arms will be split between GSK’s research base in Stevenage, U.K., and Verily’s facilities in South San Francisco--but its official headquarters will be in the U.K. ((https://web.archive.org/web/20160802185529/https://www.fiercebiotech.com/medical-devices/gsk-and-google-s-verily-create-715m-joint-venture-bioelectronics)) |
| | ==== COVID-19 ==== |
| |
| GSK is part of the [[:COVID-19 Therapeutics Accelerator]], a "philanthropic collaboration supporting efforts to research, develop and bring effective treatments against COVID-19 to market quickly and accessibly” funded by the [[:Bill & Melinda Gates Foundation]], [[:Wellcome Trust]], [[:Mastercard]], [[:Madonna]], the [[:Chan Zuckerberg Initiative]] and the United Kingdom government.((Au-Yeung, A. (2020, April 3). //A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg’s Chan Zuckerberg Initiative.// Forbes. https://archive.ph/WGnvO)) | GSK is part of the [[:COVID-19 Therapeutics Accelerator]], a "philanthropic collaboration supporting efforts to research, develop and bring effective treatments against COVID-19 to market quickly and accessibly” funded by the [[:Bill & Melinda Gates Foundation]], [[:Wellcome Trust]], [[:Mastercard]], [[:Madonna]], the [[:Chan Zuckerberg Initiative]] and the United Kingdom government.((Au-Yeung, A. (2020, April 3). //A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg’s Chan Zuckerberg Initiative.// Forbes. https://archive.ph/WGnvO)) |